COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 27, 2025
app pub date -
Jul 29, 2022
filing date -
Jul 29, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed is a compound having a structure in formula I. The compound of the present invention has good enzyme inhibitory activity against EGFR mutants (L858R/T790M/C797S, del19/T790M/C797S, del19/C797S, L858R/C797S), a weak inhibitory effect on wild-type EGFR, and good selectivity. The compound has significant inhibitory activity against the proliferation of EGFR mutant cells, and has potential application value in the treatment of diseases related to cell proliferation. The compound of the present invention has good solubility and permeability, good in-vivo metabolic stability, high in-vivo exposure, and high bioavailability, and is a potential pharmaceutical compound.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully